NewAmsterdam Pharma Company N.V. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NewAmsterdam Pharma Company N.V. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $11.84M, a 245.68% increase year-over-year.
- NewAmsterdam Pharma Company N.V. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $11.05M, a 269.41% increase year-over-year.
- NewAmsterdam Pharma Company N.V. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $3.42M.
- NewAmsterdam Pharma Company N.V. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $2.99M.
- NewAmsterdam Pharma Company N.V. stock issued during period, value, stock options exercised for fiscal 2025 was $24.54M, a 329.72% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. stock issued during period, value, stock options exercised for fiscal 2024 was $5.71M, a 1868.97% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. stock issued during period, value, stock options exercised for fiscal 2023 was $290.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $11.84M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $11.05M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $24.54M 10-K · filed 2026-02-18 | |
| 2025-06-30 | $3.42M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $2.99M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $5.71M 10-K · filed 2026-02-18 | |
| 2024-09-30 | $58.00K 10-Q · filed 2024-11-06 | |
| 2024-03-31 | -$549.00K 10-Q · filed 2024-11-06 | |
| 2023-12-31 | $290.00K 10-K · filed 2026-02-18 | |
| 2023-09-30 | $185.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $105.00K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |